ClinicalTrials.gg
RecruitingNCT05879367Updated Jun 25, 2025

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

A Phase 1 interventional study of Eflornithine (Dose Level 1) and Eflornithine (Dose Level 2) in Glioblastoma, IDH-wildtype, Glioblastoma and Glioblastoma Multiforme, sponsored by Orbus Therapeutics, Inc.. Recruiting at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Orbus Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.

Planned enrollment
268th of 1,155
66 · median 33
Started
2023
with 57 others
Phase 1
481 of 1,302
70 open now
Primary completion
2026-06
later than 60 of 322 live
Registered
1,142nd of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 268th largest by planned enrollment of the 1,155 interventional ones that give a count, is one of 58 that started in 2023, is one of 481 in phase 1, reaches primary completion later than 60 of the 322 other live ones, and was the 1,142nd registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 467 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 234 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.

Read the detailed description

This open label dose escalation and expansion study will be conducted using a standard dose-escalation design with escalating doses of eflornithine plus temozolomide at the approved dose level, followed by an expansion cohort that will further evaluate safety and preliminary efficacy of the combination at the recommended phase 2 dose.

Duration of participation will be up to approximately 104 weeks in total per patient.

Screening Period - A maximum screening duration of 4 weeks.

Treatment Period - Up to approximately 104 weeks.

Follow-Up Visit - 4 weeks from last treatment.

Long-term Survival Follow-Up - up to 2 years from last treatment.

A total of up to 66 patients will be enrolled in a non-randomized fashion (patients may be added to any of the dose levels below the RP2D to a maximum of approximately 20 per dose level with the intent of further characterizing safety and pharmacokinetics).

03

Conditions studied

  • Glioblastoma, IDH-wildtype
  • Glioblastoma
  • Glioblastoma Multiforme
  • Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
  • GBM
  • Astrocytoma
  • Astrocytoma, IDH-Mutant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of World Health Organization (WHO) G4 classified GBM, IDH-wildtype (patients with GBM) or G3 astrocytoma (IDH1 or 2 mutant; CDKN2A/B intact) per WHO 2021 tumor classification.
  • Completed external beam radiation therapy per standard of care.
  • Patients with GBM: Must have received at least 80% of planned daily doses of TMZ during chemoradiation. Patients with astrocytoma: Must have tolerated TMZ treatment through at least 2 and not more than 4 cycles.
  • Adequate hematologic, renal, hepatic, and other organ function as indicated by hematology and serum chemistry testing.
  • Willing to abstain from intercourse or use acceptable methods.
  • If taking , must be on a stable or decreasing dose.

Exclusion criteria

Exclusion Criteria:

  • Recent history of recurrent or cancer that could confound response assessments
  • Prior systemic chemotherapy other than temozolomide during external beam radiation therapy (for patients with GBM) or adjuvant temozolomide through up to 4 pre-study cycles (for patients with astrocytoma).
  • Prior Optune treatment.
  • Active infection or serious intercurrent medical illness.
  • Poorly controlled seizures.
  • Significant cardiac disease within 6 months of enrollment.
  • Poorly controlled diabetes.
  • Use of another agent within 30 days of enrollment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Eflornithine Dose Level 1 + Temozolomide

    Drug: Eflornithine (Dose Level 1) · Drug: Temozolomide

  • Experimental
    Eflornithine Dose Level 2 + Temozolomide

    Drug: Eflornithine (Dose Level 2) · Drug: Temozolomide

  • Experimental
    Eflornithine Dose Level -1 + Temozolomide

    Drug: Eflornithine (Dose Level -1) · Drug: Temozolomide

Interventions

  • Eflornithine 2.3 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule

    Also known as: DFMO

  • Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule

    Also known as: DFMO

  • Eflornithine 1.75 g/m2 administered orally every 8 hours on a 2 weeks on, 2 weeks off schedule

    Also known as: DFMO

  • Temozolomide 150 mg/m2 (with option to escalate per USPI maintenance phase instructions) administered orally once daily on a 5 days on, 23 days off schedule

    Also known as: Temodar, TMZ

06

What researchers measure

Primary outcomes

  1. Assessment of Dose Limiting Toxicities

    Protocol Defined Dose Limiting Toxicities

    Time frame: 8 weeks

  2. Incidence of TEAEs All Grades

    All Grades

    Time frame: From enrollment to the follow-up visit 4 weeks after end of treatment

  3. Incidence of TEAEs Grade 3+

    Grade 3+

    Time frame: From enrollment to the follow-up visit 4 weeks after end of treatment

  4. Incidence of TEAEs Serious

    Serious

    Time frame: From enrollment to the follow-up visit 4 weeks after end of treatment

  5. Incidence of TEAEs Leading to Discontinuation

    Leading to Discontinuation

    Time frame: From enrollment to the end of treatment

  6. Vital Signs (Heart and Respiratory Rate)

    Change from Baseline in Heart Rate and Respiratory Rate

    Time frame: From enrollment to the follow-up visit 4 weeks after end of treatment

  7. Vital Signs (Blood Pressure)

    Change from Baseline in Systolic Blood Pressure and Diastolic Blood Pressure

    Time frame: From enrollment to the follow-up visit 4 weeks after end of treatment

  8. Incidence of Treatment-Emergent Abnormalities in Clinical Laboratory Tests

    Lab abnormalities by CTCAE v5.0 Grade

    Time frame: From enrollment to the follow-up visit 4 weeks after end of treatment

Secondary outcomes

  1. Overall Survival

    Until death or initiation of new anticancer therapy

    Time frame: From enrollment to up to 2 years after last dose

  2. Progression Free Survival

    Per RANO Criteria as assessed by MRI

    Time frame: From enrollment to the follow-up visit 4 weeks after end of treatment

  3. Overall Response Rate

    Per RANO Criteria as assessed by MRI

    Time frame: From enrollment to the follow-up visit 4 weeks after end of treatment

  4. Pharmacokinetics Cmax

    observed maximum concentration

    Time frame: Baseline to Steady State (2 weeks)

  5. Pharmacokinetics Cmin

    observed minimum concentration

    Time frame: Baseline to Steady State (2 weeks)

  6. Pharmacokinetics Tmax

    time of observed maximum concentration

    Time frame: Baseline to Steady State (2 weeks)

  7. Pharmacokinetics AUCt

    area under the concentration-time curve

    Time frame: Baseline to Steady State (2 weeks)

  8. Pharmacokinetics lambdaz

    elimination rate constant

    Time frame: Baseline to Steady State (2 weeks)

  9. Pharmacokinetics t 1/2

    elimination half life

    Time frame: Baseline to Steady State (2 weeks)

  10. QTcF-Concentration Relationship

    Assessment of change in QTcF relative to plasma concentration of eflornithine

    Time frame: Baseline to Steady State (2 weeks)

  11. Assessment of QTcF

    Change from baseline in QTcF

    Time frame: Baseline to Steady State (2 weeks)

07

Study locations

7 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jun 2026, 35 months after the start.

Of 82 industry-sponsored phase 1 interventional studies under Glioblastoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's planned 35 months is below that.

Counting every sponsor, half of 322 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2023
First posted
May 30, 2023
StartActual
Jul 24, 2023
Primary completionEst.
Jun 30, 2026
CompletionEst.
Jun 30, 2026
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05879367
Lead sponsor
Orbus Therapeutics, Inc.
Responsible party
Sponsor
First posted
May 30, 2023
Start date
Jul 24, 2023
Primary completion
Jun 30, 2026 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Jun 25, 2025

Study contacts

Monika Varga
Contact
monika.varga@orbustherapeutics.com
6506569424
Howard Colman, MD, PhD
principal investigator · Huntsman Cancer Institute/ University of Utah

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eflornithine

Start the discussion